Neurocrine Biosciences Presents Ela...(results showed that elagolix had no long...),Health

"We are pleased to share this body of work with the scientific community," said Chris O'Brien, Chief Medical Officer, Neurocrine Biosciences. "An orally active gonadotropin releasing hormone antagonist with no long-term bone risk would be a significant step forward in the treatment of endometriosis and other hormone dependent diseases. These safety results support selection of the appropriate elagolix dose and regimen for the Phase III trials."

Neurocrine Biosciences also presented a preclinical study which was designed to examine the impact of a gonadotropin releasing hormone (GnRH) antagonist on prostate tissue. The animal model provided detailed information on changes in prostate size, weight, hormone levels and cell immunohistochemistry. The data reveal that transient inhibition of plasma testosterone and intra-prostatic androgens results in the reduction of prostate weight, a reduction in epithelial proliferation and suppression of prostate growth. If these preclinical results are replicated in men, daily transient inhibition of androgens with a GnRH antagonist may constitute a new paradigm for the treatment of benign prostatic hyperplasia.

About Endometriosis

Endometriosis is a painful gynecological disease that affects approximately 7.5 million women of reproductive age in the United States alone. The pain caused by endometriosis can be related to menstruation (dysmenorrhea), sexual intercourse (dyspareunia) as well as chronic pelvic pain throughout the menstrual cycle. Infertility and abnormally heavy and prolonged bleeding (menorrhagia) are also common of which, in combination with pain, contribute to more than 100,000 hysterectomies performed annually. The annual direct and indirect costs of endometriosis are estimated to exceed $20 billion in the Unites States.

Treatment options for endometri
'/>"/>